Dileep Bhateley, MD
General Practice · Marlin, TXNPI 1467456962
Payments from drug & device makers
Across 151 payments — averaging $19.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$718
- Novo Nordisk$588
- Merck$230
- Pfizer$207
- Otsuka America Pharmaceutical, Inc.$202
- GSK$191
- plus $868 from 21 others
What the payments were for
- Food & beverage$3,004100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 37 | $718 |
| Novo Nordisk | 29 | $588 |
| Merck | 9 | $230 |
| Pfizer | 6 | $207 |
| Otsuka America Pharmaceutical, Inc. | 8 | $202 |
| GSK | 11 | $191 |
| Mylan Specialty L.p. | 9 | $135 |
| Dexcom, Inc. | 9 | $134 |
| Vital Connect, Inc | 1 | $79 |
| Lilly USA, LLC | 4 | $63 |
| Amgen | 3 | $53 |
| Bayer | 3 | $49 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $48 |
| Abbott | 3 | $46 |
| Novartis | 3 | $41 |
| AstraZeneca | 2 | $32 |
| Boehringer Ingelheim | 2 | $26 |
| Bard Peripheral Vascular, Inc. | 1 | $25 |
| Exact Sciences | 1 | $22 |
| Sanofi-aventis U.S. LLC | 1 | $17 |
| Axsome Therapeutics, Inc. | 1 | $16 |
| Idorsia Pharmaceuticals US Inc | 1 | $15 |
| Johnson & Johnson | 1 | $15 |
| Amarin Pharma, Inc. | 1 | $14 |
| Innocoll Pharmaceuticals Limited | 1 | $14 |
| Sunovion Pharmaceuticals Inc. | 1 | $13 |
| Tris Pharma Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,004 in reported general payments places this provider in the 95th percentile of 8,074 general practice providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 121 | $134,777 |
| MounjaroTirzepatide | 59 | $74,332 |
| EliquisApixaban | 79 | $60,106 |
| TrulicityDulaglutide | 54 | $48,675 |
| JardianceEmpagliflozin | 59 | $46,899 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 39 | $29,399 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 40 | $27,131 |
| EntrestoSacubitril/Valsartan | 24 | $23,061 |
| XareltoRivaroxaban | 29 | $21,102 |
| JanuviaSitagliptin Phosphate | 28 | $18,722 |
| LinzessLinaclotide | 19 | $16,266 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 75 | $7,495 |
| Gabapentin | 445 | $7,480 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 16 | $5,599 |
| Humalog Kwikpen U-200Insulin Lispro | 13 | $5,553 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $588 | $134,777121 claims |
| Lilly USA, LLCMounjaro, Trulicity | $63 | $123,007113 claims |
| PfizerEliquis | $207 | $60,10679 claims |
| Boehringer IngelheimJardiance | $26 | $46,89959 claims |
| AstraZenecaBreztri Aerosphere | $32 | $29,39939 claims |
| GSKTrelegy Ellipta | $191 | $27,13140 claims |
| NovartisEntresto | $41 | $23,06124 claims |
| Johnson & JohnsonXarelto | $15 | $21,10229 claims |
| MerckJanuvia | $230 | $18,72228 claims |
| AbbVieLinzess, Synthroid | $718 | $18,03647 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,074 general practice providers in Texas.
Other general practice in Marlin
- Olusoji AfuwapeDallas$12.3M
- Karen CummingsPlano$8.4M
- Helen ShpatsHouston$3.3M
- Kelechi AzuoguHouston$2.5M
- Marcus LastimadoFort Bliss$2.3M
- Christina DeanFrisco$1.9M
- Paul ShrodeMissouri City$1.2M
- Sheila SchmidtPearland$811K
- Danielle CoulterSan Antonio$681K
- Alan DouglasSan Antonio$609K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.